Oslo, Norway

Erlend B Smeland

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 23.2

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:

goldMedal7 out of 3,435 
 
National Institutes of Health, a Component of the US Dept. of Health & Human Services
 patents
silverMedal7 out of 21 
 
Hospital Clinic De Barcelona
 patents
bronzeMedal6 out of 61 
 
British Columbia Cancer Agency Branch
 patents
46 out of 47 
 
UniversitÄt De Barcelona
 patents
56 out of 6 
 
Julius-maximilians-university of Wurzburg
 patents
66 out of 11 
 
Oslo University Hospital Hf
 patents
75 out of 972 
 
University of Arizona
 patents
85 out of 730 
 
University of Nebraska
 patents
95 out of 504 
 
Oregon Health & Science University
 patents
103 out of 1,036 
 
The Cleveland Clinic Foundation
 patents
113 out of 88 
 
University of London
 patents
123 out of 970 
 
University of Rochester
 patents
132 out of 1,742 
 
Mayo Foundation for Medical Education and Research
 patents
141 out of 3 
 
British Columbia Cancer Agency
 patents
151 out of 1 
 
Universitat De Barceloa
 patent
161 out of 1 
 
Institut D'investigacions Biomédiques Pi I Sunyer (Idibaps)
 patent
171 out of 1 
 
Robert Bosch Gesellschaft Feuer Medizinische Forshung Mbh
 patent
181 out of 639 
 
City of Hope
 patents
191 out of 2 
 
Fundacio Clinic
 patents
where one patent can have more than one assignee

Years Active: 2018-2023

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Inventor Spotlight: Erlend B Smeland

Introduction

Erlend B Smeland is an influential inventor based in Oslo, Norway, known for his significant contributions to the field of oncology through his innovative patents. With a remarkable portfolio of seven patents, he has dedicated his research to improving the diagnosis and treatment of lymphoma, particularly mantle cell lymphoma (MCL).

Latest Patents

Among his latest patents, one titled "Evaluation of mantle cell lymphoma and methods related thereto" provides methods to determine a survival predictor score for subjects with MCL. This invention not only aids in predicting survival outcomes but also offers guidance in selecting appropriate treatments for individuals diagnosed with this condition. Another noteworthy patent is "Method for determining lymphoma type and providing treatment," which presents a technique for distinguishing between various lymphoma types based on gene expression measurements. This invention effectively differentiates between primary mediastinal large B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL), enabling targeted treatment strategies based on specific gene expression signatures.

Career Highlights

Erlend B Smeland has worked with prominent institutions, including the United States of America as represented by the Secretary of the Department of Health and Human Services, and Hospital Clinic De Barcelona. His collaborations have allowed him to integrate clinical insights with innovative research, paving the way for advancements in cancer treatment.

Collaborations

Throughout his illustrious career, Smeland has collaborated with esteemed colleagues such as Louis M Staudt and Elaine S Jaffe. These partnerships have been instrumental in advancing the understanding of lymphoma and developing innovative solutions for patients suffering from these challenging conditions.

Conclusion

Erlend B Smeland stands out as a dedicated inventor whose work has significantly impacted the field of oncology. His innovative patents and collaborations with leading institutions and researchers underline his commitment to improving patient outcomes in the fight against lymphoma. As he continues to push the boundaries of cancer research, the medical community eagerly anticipates his future contributions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…